US FDA to remove restrictions on Teva morning-after pill, but not generics
This article was originally published in SRA
Executive Summary
The US Department of Justice on 10 June advised a New York district judge that the Obama administration intends to drop its appeal against the court's April order requiring the Food and Drug Administration to make Teva's single-pill emergency contraceptive Plan B One-Step (1.5 mg levonorgestrel tablet), commonly called the morning after pill, available without a prescription and without point-of-sale or age restrictions1.